The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | Selecting and sequencing therapies for R/R multiple myeloma
Sagar Lonial, MD, FACP, Emory University School of Medicine, Atlanta, GA, discusses the selection and sequencing of therapies for relapsed/refractory (R/R) multiple myeloma. He highlights that this depends on which prior treatment the patient is refractory to and notes the role of CAR-T therapy in earlier lines of treatment. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
